Brain amyloid imaging

Journal of Nuclear Medicine Technology

Volumn 41, Issue 1, 2013, Pages 11-18

  Rowe, Christopher C ^a   Villemagne, Victor L ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

amyloid; Alzheimer disease; PET

Indexed keywords

AMYLOID;

ACCURACY; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN LEVEL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; DEMENTIA; HUMANS; MOLECULAR IMAGING;

EID: 84875040856     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.076315     Document Type: Article

References (75)

1. Mathis CA, Bacskai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett. 2002;12:295-298.
2. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(49-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23:2086-2092.
3. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306-319.
4. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129-135.
5. 18F-AV-45 (florbetapir F 18). J Nucl Med. 2010;51:913-920.
6. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-283.
7. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319-329.
8. 18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424-435.
9. 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210-1217.
10. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63:674-681.
11. Johnson N, Davis T, Bosanquet N. The epidemic of Alzheimer's disease: how can we manage the costs? Pharmacoeconomics. 2000;18:215-223.
12. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-372.
13. Jellinger KA, Bancher C. Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl. 1998;54:77-95.
14. Masters CL. Neuropathology of Alzheimer's disease. In: Burns A, O'Brien J, Ames D, eds. Dementia. 3rd ed. London, U.K.: Hodder Arnold; 2005:393-407.
15. Braak H, Braak E. Staging of Alzheimer-related cortical destruction. Int Psychogeriatr. 1997;9(suppl 1):257-261.
16. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351-357.
17. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631-639.
18. Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283: 1571-1577.
19. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Ab amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860-866.
20. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem. 2006;97:1700-1725.
21. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184-185.
22. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997;20:154-159.
23. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron. 2001;32:181-184.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
25. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence based review)-report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153.
26. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
27. Clark CM, Davatzikos C, Borthakur A, et al. Biomarkers for early detection of Alzheimer pathology. Neurosignals. 2008;16:11-18.
28. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann Neurol. 2006;59:512-519.
29. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119-128.
30. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6:295-303.
31. de Leon MJ, Convit A, DeSanti S, et al. Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease. Int Psychogeriatr. 1997;9:183-190.
32. Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000; 47:430-439.
33. Xu Y, Jack CR Jr, O'Brien PC, et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology. 2000;54:1760-1767.
34. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127.
35. 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med. 2007;48:547-552.
36. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718-1725.
37. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56:303-308.
38. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia. 2000;15:93-101.
39. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-1127.
40. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
41. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133-1142.
42. Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27:22-31.
43. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45:358-368.
44. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837-1844.
45. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-1283.
46. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181-192.
47. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-292.
48. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain. 2006; 129:2823-2839.
49. Lockhart A, Ye L, Judd DB, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem. 2005;280:7677-7684.
50. Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A. Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem. 2005;280:23599-23604.
51. Nordberg A. Amyloid imaging in Alzheimer's disease. Curr Opin Neurol. 2007; 20:398-402.
52. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343-349.
53. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837-2844.
54. Villemagne VL, Pike KE, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008;46:1688-1697.
55. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431-434.
56. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630-1645.
57. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol. 2008;65:1304-1309.
58. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-452.
59. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509-1517.
60. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977-1981.
61. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2009;106:6820-6825.
62. 11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603-1606.
63. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528-1547.
64. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456-1465.
65. 11C-PIB PET study. Neurology. 2009;73:754-760.
66. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229-234.
67. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology. 2010; 74:487-493.
68. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174-6184.
69. 11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain. 2008;131:1845-1853.
70. Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66:1537-1544.
71. FDA Advisory Committee Briefing Document: NDA #202-008-Florbetapir F18 Injection. U.S. Food and Drug Administration Web site. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria ls/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM2402 66.pdf.
72. Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009;66:1557-1562.
73. Drzezga A, Grimmer T, Henriksen G, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2008;39:619-633.
74. Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2008;35:100-106.
75. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205-1212.